
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3597357/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	CYP2D6 and CYP2C19 genotype-based dose recommendations for antidepressants:â€`a first step towards subpopulation-specific dosages. Acta Psychiatrica Scandinavica, 2001, 104, 173-192.	2.2	367
2	Influence of CYP2C9 and CYP2C19 genetic polymorphisms on warfarin maintenance dose and metabolic clearance. Clinical Pharmacology and Therapeutics, 2002, 72, 702-710.	2.3	322
3	Clinically relevant pharmacokinetic drug interactions with second-generation antidepressants: An update. Clinical Therapeutics, 2008, 30, 1206-1227.	1.1	312
4	Clinically Significant Pharmacokinetic Drug Interactions with Carbamazepine. Clinical Pharmacokinetics, 1996, 31, 198-214.	1.6	284
5	Metabolic Drug Interactions with Newer Antipsychotics: A Comparative Review. Basic and Clinical Pharmacology and Toxicology, 2007, 100, 4-22.	1.2	223
6	Quetiapine and Clozapine in Parkinsonian Patients With Dopaminergic Psychosis. Clinical Neuropharmacology, 2004, 27, 153-156.	0.2	193
7	Allele and genotype frequencies of CYP2C9, CYP2C19 and CYP2D6 in an Italian population. Pharmacological Research, 2004, 50, 195-200.	3.1	190
8	Genetic polymorphism of cytochrome P450 2C9 in a Caucasian and a black African population. British Journal of Clinical Pharmacology, 2001, 52, 447-450.	1.1	186
9	Sertindole: pharmacological and clinical profile and role in the treatment of schizophrenia. Expert Opinion on Drug Metabolism and Toxicology, 2008, 4, 629-638.	1.5	180
10	Cytochrome P450 2D6 genotype and steady state plasma levels of risperidone and 9-hydroxyrisperidone. Psychopharmacology, 1999, 147, 300-305.	1.5	177
11	Antiepileptic drugs: indications other than epilepsy. Epileptic Disorders, 2004, 6, 57-75.	0.7	167
12	Relationship between plasma concentrations of clozapine and norclozapine and therapeutic response in patients with schizophrenia resistant to conventional neuroleptics. Psychopharmacology, 2000, 148, 83-89.	1.5	158
13	Metabolic drug interactions with new psychotropic agents. Fundamental and Clinical Pharmacology, 2003, 17, 517-538.	1.0	152
14	Effect of Fluvoxamine on the Pharmacokinetics of Imipramine and Desipramine in Healthy Subjects. Therapeutic Drug Monitoring, 1993, 15, 243-246.	1.0	140
15	Clinically Significant Drug Interactions with Newer Antidepressants. CNS Drugs, 2012, 26, 39-67.	2.7	135
16	Plasma Concentrations of Risperidone and 9-Hydroxyrisperidone: Effect of Comedication With Carbamazepine or Valproate. Therapeutic Drug Monitoring, 2000, 22, 481-485.	1.0	132
17	Clinical Significance of Pharmacokinetic Interactions Between Antiepileptic and Psychotropic Drugs. Epilepsia, 2002, 43, 37-44.	2.6	126
18	The economic burden of preventable adverse drug reactions: a systematic review of observational studies. Expert Opinion on Drug Safety, 2018, 17, 681-695.	1.0	125

#	Article	IF	CITATIONS
19	Clinical applications of CYP genotyping in psychiatry. Journal of Neural Transmission, 2015, 122, 5-28.	1.4	122
20	Clinically Significant Drug Interactions with Antidepressants in the Elderly. Drugs and Aging, 2002, 19, 299-320.	1.3	120
21	Age-related Changes in Pharmacodynamics: Focus on Drugs Acting on Central Nervous and Cardiovascular Systems. Current Drug Metabolism, 2011, 12, 611-620.	0.7	119
22	Relationship between plasma risperidone and 9-hydroxyrisperidone concentrations and clinical response in patients with schizophrenia. Psychopharmacology, 2001, 153, 238-243.	1.5	112
23	An International Adult Guideline for Making Clozapine Titration Safer by Using Six Ancestry-Based Personalized Dosing Titrations, CRP, and Clozapine Levels. Pharmacopsychiatry, 2022, 55, 73-86.	1.7	107
24	Plasma Concentrations of Risperidone and 9-Hydroxyrisperidone During Combined Treatment With Paroxetine. Therapeutic Drug Monitoring, 2001, 23, 223-227.	1.0	106
25	Different enantioselective 9-hydroxylation of risperidone by the two human CYP2D6 and CYP3A4 enzymes. Drug Metabolism and Disposition, 2001, 29, 1263-8.	1.7	106
26	Inhibition of Risperidone Metabolism by Fluoxetine in Patients With Schizophrenia: A Clinically Relevant Pharmacokinetic Drug Interaction. Journal of Clinical Psychopharmacology, 2002, 22, 419-423.	0.7	103
27	Relationship between plasma desipramine levels, CYP2D6 phenotype and clinical response to desipramine: a prospective study. European Journal of Clinical Pharmacology, 1997, 51, 395-398.	0.8	101
28	Effect of Aripiprazole Augmentation of Serotonin Reuptake Inhibitors or Clomipramine in Treatment-Resistant Obsessive-Compulsive Disorder. Journal of Clinical Psychopharmacology, 2011, 31, 174-179.	0.7	101
29	Adverse Drug Reactions in Hospitalized Patients: Results of the FORWARD (Facilitation of Reporting in) Tj ETQc	1110.7843 1.6	314.rgBT /Ov
30	Antidepressant Drugs and Seizure Susceptibility: From In Vitro Data to Clinical Practice. Epilepsia, 1999, 40, s48-s56.	2.6	97
31	Phenotypic consistency in hydroxylation of desmethylimipramine and debrisoquine in healthy subjects and in human liver microsomes. Clinical Pharmacology and Therapeutics, 1984, 36, 677-682.	2.3	96
32	Inhibition of desmethylimipramine 2-hydroxylation by drugs in human liver microsomes. Biochemical Pharmacology, 1985, 34, 2501-2505.	2.0	96
33	Influence of CYP2C9, 2C19 and 2D6 Genetic Polymorphisms on the Steady-State Plasma Concentrations of the Enantiomers of Fluoxetine and Norfluoxetine. Basic and Clinical Pharmacology and Toxicology, 2005, 97, 296-301.	1.2	94
34	Inhibition of diazepam metabolism by fluvoxamine: A pharmacokinetic study in normal volunteers. Clinical Pharmacology and Therapeutics, 1994, 56, 471-476.	2.3	93
35	The effect of lamotrigine augmentation of clozapine in a sample of treatment-resistant schizophrenic patients: A double-blind, placebo-controlled study. Schizophrenia Research, 2007, 93, 109-116.	1.1	93
36	Antipsychotic-induced extrapyramidal symptoms in patients with schizophrenia: associations with dopamine and serotonin receptor and transporter polymorphisms. European Journal of Clinical Pharmacology, 2007, 63, 233-241.	0.8	93

#	Article	IF	CITATIONS
37	Use of antipsychotics in elderly patients with dementia: Do atypical and conventional agents have a similar safety profile?. Pharmacological Research, 2009, 59, 1-12.	3.1	93
38	Clinically relevant interactions between newer antidepressants and second-generation antipsychotics. Expert Opinion on Drug Metabolism and Toxicology, 2014, 10, 721-746.	1.5	93
39	CYP2D6 genotype and antipsychotic-induced extrapyramidal side effects in schizophrenic patients. European Journal of Clinical Pharmacology, 2000, 56, 679-683.	0.8	91
40	Estimating the Size of the Effects of Co-Medications on Plasma Clozapine Concentrations using a Model that Controls for Clozapine Doses and Confounding Variables. Pharmacopsychiatry, 2008, 41, 81-91.	1.7	91
41	Adjunctive fluoxetine in the treatment of negative symptoms in chronic schizophrenic patients. International Clinical Psychopharmacology, 1994, 9, 281-286.	0.9	90
42	Risk of stroke with typical and atypical anti-psychotics: a retrospective cohort study including unexposed subjects. Journal of Psychopharmacology, 2008, 22, 39-46.	2.0	89
43	Lamotrigine augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive–compulsive disorder: a double-blind, placebo-controlled study. Journal of Psychopharmacology, 2012, 26, 1456-1462.	2.0	87
44	Risperidone Treatment of Children with Autistic Disorder: Effectiveness, Tolerability, and Pharmacokinetic Implications. Journal of Child and Adolescent Psychopharmacology, 2004, 14, 39-47.	0.7	86
45	Clinically significant pharmacokinetic drug interactions of antiepileptic drugs with new antipsychotics. Pharmacological Research, 2016, 106, 72-86.	3.1	85
46	Small Effects of Valproic Acid on the Plasma Concentrations of Clozapine and its Major Metabolites in Patients With Schizophrenic or Affective Disorders. Therapeutic Drug Monitoring, 1999, 21, 341.	1.0	84
47	The effect of mirtazapine augmentation of clozapine in the treatment of negative symptoms of schizophrenia: a double-blind, placebo-controlled study. International Clinical Psychopharmacology, 2004, 19, 71-76.	0.9	83
48	Assessing drug-drug interactions through therapeutic drug monitoring when administering oral second-generation antipsychotics. Expert Opinion on Drug Metabolism and Toxicology, 2016, 12, 407-422.	1.5	82
49	Determination of risperidone and its major metabolite 9-hydroxyrisperidone in human plasma by reversed-phase liquid chromatography with ultraviolet detection. Biomedical Applications, 2000, 746, 173-181.	1.7	81
50	Prescribing patterns of antiepileptic drugs in Italy: a nationwide populationâ€based study in the years 2000–2005. European Journal of Neurology, 2007, 14, 1317-1321.	1.7	81
51	Interaction Between Fluvoxamine and Imipramine/Desipramine in Four Patients. Therapeutic Drug Monitoring, 1992, 14, 194-196.	1.0	76
52	Effect of aripiprazole augmentation of clozapine in schizophrenia: A double-blind, placebo-controlled study. Schizophrenia Research, 2011, 127, 93-99.	1.1	76
53	Melatonin treatment mimics the antidepressant action in chronic corticosterone-treated mice. Journal of Pineal Research, 2010, 49, no-no.	3.4	73
54	Pharmacogenetics of Antidepressants. Frontiers in Pharmacology, 2011, 2, 6.	1.6	72

#	Article	IF	CITATIONS
55	Effect of fluoxetine on the plasma concentrations of clozapine and its major metabolites in patients with schizophrenia. International Clinical Psychopharmacology, 1998, 13, 141.	0.9	70
56	Generalized versus partial reflex seizures: A review. Seizure: the Journal of the British Epilepsy Association, 2014, 23, 512-520.	0.9	70
57	Clinical Pharmacokinetics of Fluvoxamine. Clinical Pharmacokinetics, 1994, 27, 175-190.	1.6	69
58	Metabolic Drug Interactions Between Antidepressants and Anticancer Drugs: Focus on Selective Serotonin Reuptake Inhibitors and Hypericum Extract. Current Drug Metabolism, 2011, 12, 570-577.	0.7	69
59	A systematic review and combined analysis of therapeutic drug monitoring studies for long-acting risperidone. Expert Review of Clinical Pharmacology, 2017, 10, 965-981.	1.3	69
60	A comprehensive review of the clinical utility of and a combined analysis of the clozapine/norclozapine ratio in therapeutic drug monitoring for adult patients. Expert Review of Clinical Pharmacology, 2019, 12, 603-621.	1.3	69
61	Inhibition of desipramine 2-hydroxylation by quinidine and quinine. Clinical Pharmacology and Therapeutics, 1988, 43, 577-581.	2.3	67
62	Plasma Concentrations of Clozapine and its Major Metabolites During Combined Treatment with Paroxetine or Sertraline. Pharmacopsychiatry, 2000, 33, 213-217.	1.7	67
63	Clobazam Therapeutic Drug Monitoring. Therapeutic Drug Monitoring, 2013, 35, 30-47.	1.0	67
64	Debrisoquine oxidation phenotype during neuroleptic monotherapy. European Journal of Clinical Pharmacology, 1991, 41, 467-470.	0.8	66
65	Genetic polymorphisms of cytochrome P450 enzymes and antidepressant metabolism. Expert Opinion on Drug Metabolism and Toxicology, 2011, 7, 1101-1115.	1.5	64
66	Interactions between antiepileptics and second-generation antipsychotics. Expert Opinion on Drug Metabolism and Toxicology, 2012, 8, 311-334.	1.5	64
67	Severe phenytoin intoxication in a subject homozygous for CYP2C9*3. Clinical Pharmacology and Therapeutics, 2001, 70, 391-4.	2.3	64
68	Further evidence for the association between 5-HT2C receptor gene polymorphisms and extrapyramidal side effects in male schizophrenic patients. European Journal of Clinical Pharmacology, 2008, 64, 477-482.	0.8	61
69	Antipsychotics and Torsadogenic Risk: Signals Emerging from the US FDA Adverse Event Reporting System Database. Drug Safety, 2013, 36, 467-479.	1.4	61
70	Genetics of reflex seizures and epilepsies in humans and animals. Epilepsy Research, 2016, 121, 47-54.	0.8	60
71	Antidepressant drugs: prevalence, incidence and indication of use in general practice of Southern Italy during the years 2003–2004. Pharmacoepidemiology and Drug Safety, 2007, 16, 552-559.	0.9	59
72	Antidepressant use in the elderly: the role of pharmacodynamics and pharmacokinetics in drug safety. Expert Opinion on Drug Metabolism and Toxicology, 2015, 11, 883-892.	1.5	59

#	Article	IF	CITATIONS
73	Clozapine Metabolism in East Asians and Caucasians. Journal of Clinical Psychopharmacology, 2019, 39, 135-144.	0.7	58
74	ABCB1 Polymorphisms Influence Steady-State Plasma Levels of 9-Hydroxyrisperidone and Risperidone Active Moiety. Therapeutic Drug Monitoring, 2008, 30, 628-633.	1.0	56
75	Olanzapine augmentation of paroxetine-refractory obsessive-compulsive disorder. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2003, 27, 619-623.	2.5	55
76	Ziprasidone and amisulpride effectively treat negative symptoms of schizophrenia: results of a 12-week, double-blind study. International Clinical Psychopharmacology, 2006, 21, 143-151.	0.9	55
77	Antipsychotic prescribing pattern among Italian general practitioners: a population-based study during the years 1999?2002. European Journal of Clinical Pharmacology, 2005, 61, 47-53.	0.8	54
78	Quetiapine versus clozapine: a preliminary report of comparative effects on dopaminergic psychosis in patients with Parkinson's disease. Neurological Sciences, 2002, 23, s89-s90.	0.9	53
79	CONTINUOUS APOMORPHINE INFUSION (CAI) AND NEUROPSYCHIATRIC DISORDERS IN PATIENTS WITH ADVANCED PARKINSON'S DISEASE: A FOLLOW-UP OF TWO YEARS. Archives of Gerontology and Geriatrics, 2004, 38, 291-296.	1.4	53
80	A comprehensive review of swallowing difficulties and dysphagia associated with antipsychotics in adults. Expert Review of Clinical Pharmacology, 2019, 12, 219-234.	1.3	53
81	Polymorphic debrisoquine oxidation and acute neuroleptic-induced adverse effects. European Journal of Clinical Pharmacology, 1992, 42, 347-348.	0.8	52
82	Carbamazepine Coadministration with Fluoxetine or Fluvoxamine. Therapeutic Drug Monitoring, 1993, 15, 247-250.	1.0	52
83	Cytochrome P450 polymorphisms and response to antipsychotic therapy. Pharmacogenomics, 2002, 3, 201-218.	0.6	51
84	Can Valproic Acid be an Inducer of Clozapine Metabolism?. Pharmacopsychiatry, 2014, 47, 89-96.	1.7	50
85	Hydroxylation of desmethylimipramine: Dependence on the debrisoquin hydroxylation phenotype. Clinical Pharmacology and Therapeutics, 1987, 41, 314-319.	2.3	49
86	Short-Term Memory Loss Associated with Rosuvastatin. Pharmacotherapy, 2006, 26, 1190-1192.	1.2	48
87	Pharmacokinetic and pharmacodynamic interactions between antiepileptics and antidepressants. Expert Opinion on Drug Metabolism and Toxicology, 2014, 10, 1457-1489.	1.5	47
88	Differences in the inhibitory effect of cimetidine on desipramine metabolism between rapid and slow debrisoquin hydroxylators. Clinical Pharmacology and Therapeutics, 1987, 42, 278-282.	2.3	45
89	Estimating the effects of co-medications on plasma olanzapine concentrations by using a mixed model. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2008, 32, 1453-1458.	2.5	45
90	Improved enantioselective assay for the determination of fluoxetine and norfluoxetine enantiomers in human plasma by liquid chromatography. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2003, 784, 375-383.	1.2	44

#	Article	IF	CITATIONS
91	Hypericum perforatum treatment: effect on behaviour and neurogenesis in a chronic stress model in mice. BMC Complementary and Alternative Medicine, 2011, 11, 7.	3.7	44
92	Effect of Adjunctive Lamotrigine Treatment on the Plasma Concentrations of Clozapine, Risperidone and Olanzapine in Patients With Schizophrenia or Bipolar Disorder. Therapeutic Drug Monitoring, 2006, 28, 599-602.	1.0	43
93	Prescribing pattern of antiâ€epileptic drugs in an Italian setting of elderly outpatients: a populationâ€based study during 2004‰07. British Journal of Clinical Pharmacology, 2010, 70, 514-522.	1.1	41
94	Determination of clozapine, desmethylclozapine and clozapine N-oxide in human plasma by reversed-phase high-performance liquid chromatography with ultraviolet detection. Biomedical Applications, 1998, 714, 299-308.	1.7	40
95	The pharmacology and safety of paliperidone extended-release in the treatment of schizophrenia. Expert Opinion on Drug Safety, 2007, 6, 651-662.	1.0	40
96	Effect of Valproate on Olanzapine Plasma Concentrations in Patients With Bipolar or Schizoaffective Disorder. Therapeutic Drug Monitoring, 2009, 31, 758-763.	1.0	40
97	Safety profiles of biologic agents for inflammatory bowel diseases: a prospective pharmacovigilance study in Southern Italy. Current Medical Research and Opinion, 2020, 36, 1457-1463.	0.9	40
98	Inducing Effect of Phenobarbital on Clozapine Metabolism in Patients With Chronic Schizophrenia. Therapeutic Drug Monitoring, 1998, 20, 628-630.	1.0	40
99	Plasma Concentrations of the Enantiomers of Fluoxetine and Norfluoxetine: Sources of Variability and Preliminary Observations on Relations With Clinical Response. Therapeutic Drug Monitoring, 2002, 24, 616-627.	1.0	39
100	Lack of a pharmacokinetic interaction between mirtazapine and the newer antipsychotics clozapine, risperidone and olanzapine in patients with chronic schizophrenia. Pharmacological Research, 2003, 48, 411-414.	3.1	39
101	Adverse Drug Interaction Between Risperidone and Carbamazepine in a Patient With Chronic Schizophrenia and Deficient CYP2D6 Activity. Journal of Clinical Psychopharmacology, 2001, 21, 108-109.	0.7	38
102	Short- and long-term effects on prolactin of risperidone and olanzapine treatments in children and adolescents. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2009, 33, 1496-1501.	2.5	38
103	Evaluation of the role of MAPK1 and CREB1 polymorphisms on treatment resistance, response and remission in mood disorder patients. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2013, 44, 271-278.	2.5	38
104	Interaction of Carbamazepineâ€10,11â€Epoxide, an Active Metabolite of Carbamazepine, with Valproate: A Pharmacokinetic Study. Epilepsia, 1990, 31, 339-342.	2.6	37
105	Plasma Concentrations of Risperidone and Olanzapine during Coadministration with Oxcarbazepine. Epilepsia, 2005, 46, 771-774.	2.6	37
106	A systematic review and combined analysis of therapeutic drug monitoring studies for long-acting paliperidone. Expert Review of Clinical Pharmacology, 2018, 11, 1237-1253.	1.3	37
107	Determination of Olanzapine in Human Plasma by Reversed-phase High-performance Liquid Chromatography With Ultraviolet Detection. Therapeutic Drug Monitoring, 2006, 28, 388-393.	1.0	36
108	Clinically relevant drug interactions in anxiety disorders. Human Psychopharmacology, 2012, 27, 239-253.	0.7	36

#	Article	IF	CITATIONS
109	Newer and older antiepileptic drug use in Southern Italy: A population-based study during the years 2003–2005. Epilepsy Research, 2009, 85, 107-113.	0.8	35
110	Effect of ketoconazole on the pharmacokinetics of imipramine and desipramine in healthy subjects. British Journal of Clinical Pharmacology, 1997, 43, 315-318.	1.1	34
111	Preliminary agenda, ASCPT 2002 annual meetingAtlanta, Georgia March 24–28. Clinical Pharmacology and Therapeutics, 2001, 70, 403-404.	2.3	34
112	Duloxetine as adjunctive treatment to clozapine in patients with schizophrenia. International Clinical Psychopharmacology, 2011, 26, 303-310.	0.9	34
113	Are the Safety Profiles of Antipsychotic Drugs Used in Dementia the Same? An Updated Review of Observational Studies. Drug Safety, 2014, 37, 501-520.	1.4	34
114	Indications of newer and older antiâ€epileptic drug use: findings from a southern Italian general practice setting from 2005–2011. British Journal of Clinical Pharmacology, 2015, 79, 1010-1019.	1.1	34
115	A systematic review and combined analysis of therapeutic drug monitoring studies for oral paliperidone. Expert Review of Clinical Pharmacology, 2018, 11, 625-639.	1.3	34
116	The Effect of Safety Warnings on Antipsychotic Drug Prescribing in Elderly Persons with Dementia in the United Kingdom and Italy: A Population-Based Study. CNS Drugs, 2016, 30, 1097-1109.	2.7	33
117	Neuropsychiatric reactions to drugs: an analysis of spontaneous reports from general practitioners in Italy. Pharmacological Research, 2005, 51, 211-216.	3.1	32
118	Clinical trial methodology to assess the efficacy/effectiveness of long-acting antipsychotics: Randomized controlled trials vs naturalistic studies. Psychiatry Research, 2017, 247, 257-264.	1.7	32
119	Phenobarbital Induces the 2-Hydroxylation of Desipramine. Therapeutic Drug Monitoring, 1996, 18, 60-64.	1.0	32
120	Changes in the prescribing pattern of antidepressant drugs in elderly patients: an Italian, nationwide, population-based study. European Journal of Clinical Pharmacology, 2014, 70, 469-478.	0.8	31
121	Possible Pharmacodynamic and Pharmacokinetic Drug-Drug Interactions That Are Likely to Be Clinically Relevant and/or Frequent in Bipolar Disorder. Current Psychiatry Reports, 2018, 20, 17.	2.1	31
122	Pharmacokinetic Optimisation of Tricyclic Antidepressant Therapy. Clinical Pharmacokinetics, 1993, 24, 301-318.	1.6	30
123	No Effect of Citalopram on Plasma Levels of Clozapine, Risperidone and their Active Metabolites in Patients with Chronic Schizophrenia. Clinical Drug Investigation, 1998, 16, 393-398.	1.1	30
124	Restless Leg Syndrome in ADHD children: Levetiracetam as a reasonable therapeutic option. Brain and Development, 2011, 33, 480-486.	0.6	30
125	Progress and prospects in pharmacogenetics of antidepressant drugs. Expert Opinion on Drug Metabolism and Toxicology, 2016, 12, 1157-1168.	1.5	30
126	An update on the complex relationship between clozapine and pneumonia. Expert Review of Clinical Pharmacology, 2021, 14, 145-149.	1.3	30

#	Article	IF	CITATIONS
127	Single dose pharmacokinetics of carbamazepine-10,11-epoxide in patients on lamotrigine monotherapy. Epilepsy Research, 1994, 19, 245-248.	0.8	29
128	Melatonin's stimulatory effect on adult hippocampal neurogenesis in mice persists after ovariectomy. Journal of Pineal Research, 2011, 51, 353-360.	3.4	29
129	Management of women with epilepsy: from preconception to post-partum. Archives of Gynecology and Obstetrics, 2016, 293, 493-503.	0.8	29
130	Elevation of Plasma Carbamazepine Concentrations by Ketoconazole in Patients With Epilepsy. Therapeutic Drug Monitoring, 1997, 19, 535-538.	1.0	29
131	Prescribing pattern of anti-Parkinson drugs in Southern Italy: Cross-sectional analysis in the years 2003–2005. Parkinsonism and Related Disorders, 2008, 14, 420-425.	1.1	28
132	A nationwide prospective study on prescribing pattern of antidepressant drugs in Italian primary care. European Journal of Clinical Pharmacology, 2013, 69, 227-236.	0.8	28
133	Carbamazepine induced bradycardia - a problem in general or only in susceptible patients? A 24-h long-term electrocardiogram study. Epilepsy Research, 1992, 13, 141-145.	0.8	27
134	Plasma Risperidone Concentrations During Combined Treatment with Sertraline. Therapeutic Drug Monitoring, 2004, 26, 386-390.	1.0	27
135	Clinically relevant drug interactions between newer antidepressants and oral anticoagulants. Expert Opinion on Drug Metabolism and Toxicology, 2020, 16, 31-44.	1.5	27
136	Effect of valpromide on the pharmacokinetics of carbamazepineâ€10, 11―epoxide British Journal of Clinical Pharmacology, 1988, 25, 611-613.	1.1	26
137	Newer and Older Antidepressants. CNS Drugs, 1994, 2, 479-497.	2.7	26
138	The effect of carbamazepine on the 2-hydroxylation of desipramine. Psychopharmacology, 1995, 117, 413-416.	1.5	26
139	Head-to-Head Comparison of Aripiprazole and Risperidone in the Treatment of ADHD Symptoms in Children with Autistic Spectrum Disorder and ADHD: A Pilot, Open-Label, Randomized Controlled Study. Paediatric Drugs, 2016, 18, 319-329.	1.3	26
140	Augmentation of Clozapine With Ziprasidone in Refractory Schizophrenia. Journal of Clinical Psychopharmacology, 2014, 34, 129-133.	0.7	25
141	Prevalence of acute dystonic reactions associated with neuroleptic treatment with and without anticholinergic prophylaxis. International Clinical Psychopharmacology, 1993, 8, 21-24.	0.9	24
142	Effect of Topiramate on Plasma Concentrations of Clozapine, Olanzapine, Risperidone, and Quetiapine in Patients With Psychotic Disorders. Clinical Neuropharmacology, 2007, 30, 107-113.	0.2	24
143	Clinically relevant drug interactions between statins and antidepressants. Journal of Clinical Pharmacy and Therapeutics, 2020, 45, 227-239.	0.7	24
144	No Effect of the New Antidepressant Reboxetine on CYP2D6 Activity in Healthy Volunteers. Therapeutic Drug Monitoring, 1999, 21, 577.	1.0	24

#	Article	IF	CITATIONS
145	Glutamine-supplemented total parenteral nutrition improves immunological status in anorectic patients. Nutrition, 2010, 26, 677-681.	1.1	23
146	nâ~'3 fatty acids prevent impairment of neurogenesis and synaptic plasticity in B-cell activating factor (BAFF) transgenic mice. Preventive Medicine, 2012, 54, S103-S108.	1.6	23
147	Ototoxic Adverse Drug Reactions: A Disproportionality Analysis Using the Italian Spontaneous Reporting Database. Frontiers in Pharmacology, 2019, 10, 1161.	1.6	23
148	Debrisoquine oxidation phenotype and neurolepticâ€induced dystonic reactions. Acta Psychiatrica Scandinavica, 1992, 86, 364-366.	2.2	22
149	Duloxetine in Psychiatric Disorders: Expansions Beyond Major Depression and Generalized Anxiety Disorder. Frontiers in Psychiatry, 2019, 10, 772.	1.3	22
150	Single-Dose Kinetics of an Enteric-Coated Formulation of Carbamazepine-10,11-epoxide, an Active Metabolite of Carbamazepine. Therapeutic Drug Monitoring, 1988, 10, 386-389.	1.0	21
151	Use and tolerability of newer antipsychotics and antidepressants: a chart review in a paediatric setting. International Journal of Clinical Pharmacy, 2007, 30, 44-50.	1.4	21
152	Clinically Relevant Interactions between Atypical Antipsychotics and Anti-Infective Agents. Pharmaceuticals, 2020, 13, 439.	1.7	21
153	Oxidation of tricyclic antidepressant drugs, debrisoquine and 7-ethoxyresorufin, by human liver preparations. Xenobiotica, 1986, 16, 391-400.	0.5	20
154	CYP2D6-related oxidation polymorphism in Italy. Pharmacological Research, 1994, 29, 281-289.	3.1	20
155	Pharmacokinetic Drug Interaction Studies Must Consider Pharmacological Heterogeneity, Use of Repeated Dosing, and Translation Into a Message Understandable to Practicing Clinicians. Journal of Clinical Psychopharmacology, 2009, 29, 201-205.	0.7	20
156	Drug Dosage Individualization Based on a Random-Effects Linear Model. Journal of Biopharmaceutical Statistics, 2012, 22, 463-484.	0.4	20
157	ECG parameters in children and adolescents treated with aripiprazole and risperidone. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2014, 51, 23-27.	2.5	20
158	A molecular pathway analysis informs the genetic background at risk for schizophrenia. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2015, 59, 21-30.	2.5	20
159	Assessment and Management of Cognitive and Psychosocial Dysfunctions in Patients With Major Depressive Disorder: A Clinical Review. Frontiers in Psychiatry, 2018, 9, 493.	1.3	20
160	No Effect of Reboxetine on Plasma Concentrations of Clozapine, Risperidone, and Their Active Metabolites. Therapeutic Drug Monitoring, 2001, 23, 675-678.	1.0	19
161	Pharmaco-utilisation and related costs of drugs used to treat schizophrenia and bipolar disorder in Italy: the IBIS study. BMC Psychiatry, 2014, 14, 282.	1.1	19
162	6â€Mer Hyaluronan Oligosaccharides Modulate Neuroinflammation and αâ€Synuclein Expression in Neuronâ€Like SHâ€SY5Y Cells. Journal of Cellular Biochemistry, 2016, 117, 2835-2843.	1.2	19

#	Article	IF	CITATIONS
163	European Whites May Need Lower Minimum Therapeutic Clozapine Doses Than Those Customarily Proposed. Journal of Clinical Psychopharmacology, 2021, 41, 140-147.	0.7	19
164	Pharmacokinetics of the antidepressant drug viloxazine in normal subjects and in epileptic patients receiving chronic anticonvulsant treatment. Psychopharmacology, 1986, 90, 295-8.	1.5	18
165	Tricyclic Antidepressants Analysis by Liquid Chromatography. Journal of Liquid Chromatography and Related Technologies, 1987, 10, 223-240.	0.9	18
166	In Vitro Inhibition of a Polymorphic Human Liver P-450 Isozyme by Narcotic Analgesics. Anesthesiology, 1989, 70, 339-342.	1.3	17
167	No association between CYP2D6 polymorphism and Alzheimer's disease in an Italian population. Pharmacological Research, 2006, 53, 162-165.	3.1	17
168	Rabeprazole and Psychiatric Symptoms. Annals of Pharmacotherapy, 2007, 41, 1315-1317.	0.9	17
169	The Role of Levomilnacipran in the Management of Major Depressive Disorder: A Comprehensive Review. Current Neuropharmacology, 2016, 14, 191-199.	1.4	17
170	Tools for optimising pharmacotherapy in psychiatry (therapeutic drug monitoring, molecular brain) Tj ETQq0 0 0 Psychiatry, 2021, 22, 561-628.	rgBT /Ove 1.3	erlock 10 Tf 50 17
171	Pharmacogenetic aspects in the metabolism of psychotropic drugs: Pharmacokinetic and clinical implications. Pharmacological Research, 1994, 29, 121-137.	3.1	16
172	Evaluation of acute cardiovascular effects of immediate-release methylphenidate in children and adolescents with attention-deficit hyperactivity disorder. Neuropsychiatric Disease and Treatment, 2015, 11, 1169.	1.0	16
173	Fluvoxamine-induced alterations in plasma concentrations of imipramine and desipramine in depressed patients. International Journal of Clinical Pharmacology Research, 1993, 13, 167-71.	0.4	16
174	Differential effects of cimetidine and ranitidine on imipramine demethylation and desmethylimipramine hydroxylation by human liver microsomes. European Journal of Clinical Pharmacology, 1986, 30, 239-242.	0.8	15
175	Alprazolam Does Not Inhibit the Metabolism of Nortriptyline in Depressed Patients of Inhibit the Metabolism of Desipramine in Human Liver Microsomes. Therapeutic Drug Monitoring, 1988, 10, 231-233.	1.0	15
176	Effect of fluvoxamine on plasma risperidone concentrations in patients with schizophrenia. Pharmacological Research, 2005, 52, 497-501.	3.1	15
177	How frequently are contraindicated or warned against combinations of drugs prescribed to patients receiving longâ€ŧerm opioid therapy for chronic pain?. Pharmacoepidemiology and Drug Safety, 2012, 21, 453-462.	0.9	15
178	What is needed to incorporate clinical pharmacogenetic tests into the practice of psychopharmacotherapy?. Expert Review of Clinical Pharmacology, 2016, 9, 351-354.	1.3	15
179	Adverse Drug Reactions with HER2-Positive Breast Cancer Treatment: An Analysis from the Italian Pharmacovigilance Database. Drugs - Real World Outcomes, 2022, 9, 91-107.	0.7	15
180	Effect of Phenobarbital on the Pharmacokinetics of Carbamazepine-10, 11-Epoxide, an Active Metabolite of Carbamazepine. Therapeutic Drug Monitoring, 1991, 13, 109-112.	1.0	14

#	Article	IF	CITATIONS
181	Effects of L'Aquila earthquake on the prescribing pattern of antidepressant and antipsychotic drugs. International Journal of Clinical Pharmacy, 2013, 35, 1053-1062.	1.0	14
182	Pharmacogenetics of drug-metabolizing enzymes in Italian populations. Drug Metabolism and Personalized Therapy, 2015, 30, 107-120.	0.3	14
183	Characterization and preventability of adverse drug events as cause of emergency department visits: a prospective 1-year observational study. BMC Pharmacology & amp; Toxicology, 2019, 20, 21.	1.0	14
184	Safety Profile of Biologics Used in Rheumatology: An Italian Prospective Pharmacovigilance Study. Journal of Clinical Medicine, 2020, 9, 1227.	1.0	14
185	Pharmacokinetic Drug-Drug Interactions Between Olanzapine and Valproate Need to Be Better Studied. Journal of Clinical Psychiatry, 2010, 71, 957-958.	1.1	14
186	Screening the European pharmacovigilance database for reports of clozapine-related DRESS syndrome: 47 novel cases. European Neuropsychopharmacology, 2022, 60, 25-37.	0.3	14
187	Debrisoquine oxidation in an Italian population: A study in healthy subjects and in schizophrenic patients. Pharmacological Research, 1992, 25, 43-50.	3.1	13
188	Co-prescriptions with itraconazole and fluconazole as a signal for possible risk of drug–drug interactions: a four-year analysis from Italian general practice. Pharmacoepidemiology and Drug Safety, 2007, 16, 422-428.	0.9	13
189	Safety and Tolerability of Antipsychotic Drugs in Pediatric Patients: Data From a 1-Year Naturalistic Study. Frontiers in Psychiatry, 2020, 11, 152.	1.3	13
190	Pediatric adverse reactions to antiseizure medications – An analysis of data from the Italian spontaneous reporting system (2001–2019). Epilepsy and Behavior, 2021, 119, 107989.	0.9	13
191	Potentially Clinically Relevant Pharmacodynamic Interactions Between Antiepileptic Drugs and Psychotropic Drugs: An Update. Current Pharmaceutical Design, 2018, 23, 5625-5638.	0.9	13
192	Preclinical Data Supporting/Refuting the Use of Hypericum perforatum in the Treatment of Depression. CNS and Neurological Disorders - Drug Targets, 2013, 12, 474-486.	0.8	13
193	Newer antipsychotics: comparative review of drug interactions. Expert Review of Neurotherapeutics, 2001, 1, 171-182.	1.4	12
194	Safety and Efficacy of Paliperidone Extended-Release in Acute and Maintenance Treatment of Schizophrenia. Journal of Central Nervous System Disease, 2011, 3, JCNSD.S1607.	0.7	12
195	Acute Cerebellar Ataxia Following Meningococcal Group C Conjugate Vaccination. Journal of Child Neurology, 2014, 29, 128-130.	0.7	12
196	Rapid versus slow withdrawal of antiepileptic monotherapy in 2-year seizure-free adult patients with epilepsy (RASLOW) study: a pragmatic multicentre, prospective, randomized, controlled study. Neurological Sciences, 2016, 37, 579-583.	0.9	12
197	A Narrative Review on Efficacy and Safety of Proton Pump Inhibitors in Children. Frontiers in Pharmacology, 2022, 13, 839972.	1.6	12
198	Interaction between fluoxetine and haloperidol: pharmacokinetic and clinical implications. Pharmacological Research, 1997, 35, 335-9.	3.1	12

#	Article	IF	CITATIONS
199	Augmentation of Clozapine With Agomelatine in Partial-Responder Schizophrenia. Journal of Clinical Psychopharmacology, 2014, 34, 491-494.	0.7	11
200	Real World Data on the Utilization Pattern and Safety Profile of Infliximab Originator Versus Biosimilars in Italy: A Multiregional Study. BioDrugs, 2018, 32, 607-617.	2.2	11
201	Early atypical injectionâ€site reactions to COVIDâ€19 vaccine: a case series. Journal of the European Academy of Dermatology and Venereology, 2022, 36, .	1.3	11
202	Adverse Drug Reactions with Drugs Used in Multiple Sclerosis: An Analysis from the Italian Pharmacovigilance Database. Frontiers in Pharmacology, 2022, 13, 808370.	1.6	11
203	Urinary Desipramine Hydroxylation Index and Steady-State Plasma Concentrations of Imipramine and Desipramine. Therapeutic Drug Monitoring, 1987, 9, 129-133.	1.0	10
204	Low-Dose of Bergamot-Derived Polyphenolic Fraction (BPF) Did Not Improve Metabolic Parameters in Second Generation Antipsychotics-Treated Patients: Results from a 60-days Open-Label Study. Frontiers in Pharmacology, 2017, 8, 197.	1.6	10
205	Vortioxetine on Cognition in Schizophrenia. Journal of Clinical Psychopharmacology, 2020, 40, 381-385.	0.7	10
206	Clinically Relevant Drug Interactions with Anti-Alzheimer's Drugs. CNS and Neurological Disorders - Drug Targets, 2017, 16, 501-513.	0.8	10
207	Venlafaxine-Induced Urinary Incontinence Resolved After Switching to Sertraline. Clinical Neuropharmacology, 2005, 28, 247-248.	0.2	9
208	Red Yeast Rice (RYR) supplementation in patients treated with second-generation antipsychotics. Complementary Therapies in Medicine, 2018, 37, 167-171.	1.3	9
209	Issues in Methodology and Applications for Therapeutic Drug Monitoring of Fluoxetine and Norfluoxetine Enantiomers. Therapeutic Drug Monitoring, 1998, 20, 20-24.	1.0	9
210	Therapeutic Drug Monitoring of Quetiapine: Effect of Coadministration with Antiepileptic Drugs in Patients with Psychiatric Disorders. The Open Clinical Chemistry Journal, 2008, 1, 17-21.	0.7	9
211	Drug interactions with vortioxetine, a new multimodal antidepressant. Rivista Di Psichiatria, 2015, 50, 210-5.	0.6	9
212	An endocrinological study of patients with primary cutis verticis gyrata Acta Dermato-Venereologica, 1993, 73, 348-349.	0.6	9
213	Analysis of Tricyclic Antidepressants in Serum and Plasma Yields Similar Results. Therapeutic Drug Monitoring, 1985, 7, 242-243.	1.0	8
214	Minor Additive Inducing Effects of Phenobarbital on Carbamazepine Clearance in Patients on Combined Carbamazepine-Phenytoin Therapy. Therapeutic Drug Monitoring, 1987, 9, 117-119.	1.0	8
215	No Effect of Thioridazine on Plasma Concentrations of Carbamazepine and Its Active Metabolite Carbamazepine-10,11-Epoxide. Therapeutic Drug Monitoring, 1990, 12, 511-513.	1.0	8
216	The effect of clozapine on aggressive behaviour in patients with chronic schizophrenia. International Journal of Psychiatry in Clinical Practice, 1999, 3, 49-54.	1.2	8

#	Article	IF	CITATIONS
217	Generic Olanzapine Substitution in Patients With Schizophrenia. Therapeutic Drug Monitoring, 2015, 37, 827-830.	1.0	8
218	Long-Term Intravitreal Ranibizumab as a Potential Additional Risk Factor for Neurodegeneration in Parkinson's Disease: A Case Report. Frontiers in Pharmacology, 2018, 9, 608.	1.6	8
219	Evidence of chromosomal fragile sites in schizophrenic patients. Annales De Génétique, 1993, 36, 132-5.	0.4	8
220	Impairment of carbamazepineâ€10, 11â€epoxide elimination by valnoctamide, a valpromide isomer, in healthy subjects British Journal of Clinical Pharmacology, 1992, 34, 85-87.	1.1	7
221	Effect of Adjunctive Duloxetine on the Plasma Concentrations of Clozapine, Olanzapine, and Risperidone in Patients With Psychotic Disorders. Journal of Clinical Psychopharmacology, 2010, 30, 634-636.	0.7	7
222	High mobility group box 1 and markers of oxidative stress in human cord blood. Pediatrics International, 2019, 61, 264-270.	0.2	7
223	Cenobamate: A Review of its Pharmacological Properties, Clinical Efficacy and Tolerability Profile in the Treatment of Epilepsy. CNS and Neurological Disorders - Drug Targets, 2023, 22, 394-403.	0.8	7
224	Diazepam Treatment Does Not Influence the Debrisoquine or Mephenytoin Hydroxylation Phenotyping Tests. Therapeutic Drug Monitoring, 1989, 11, 721-723.	1.0	6
225	Iron status in schizophrenic patients with acute neuroleptic-induced dystonic reactions. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 1994, 18, 891-898.	2.5	6
226	Predictability of metabolic antiepileptic drug interactions. , 2005, , 57-92.		6
227	Adverse drug reactions with oral anticoagulants: data from sicilian spontaneous reporting system database. Journal of Clinical Pharmacy and Therapeutics, 2021, 46, 1027-1040.	0.7	6
228	Inhibition of Desipramine 2-Hydroxylation by Quinidine and Quinine in Rapid and Slow Debrisoquine Hydroxylators. , 1989, 7, 201-205.		6
229	Evaluation of putative cytotoxic activity of crude extracts from Onopordum acanthium leaves and Spartium junceum flowers against the U-373 glioblastoma cell line. Pakistan Journal of Pharmaceutical Sciences, 2015, 28, 1225-32.	0.2	6
230	Evaluation of Tricyclic Antidepressant Plasma Levels by an Automated Enzyme Immunoassay (EMIT) in Comparison to a High-Performance Liquid Chromatographic Method. Therapeutic Drug Monitoring, 1988, 10, 333-339.	1.0	5
231	Safety profile of immune checkpoint inhibitors: An analysis of the Italian spontaneous reporting system database. British Journal of Clinical Pharmacology, 2021, 87, 527-541.	1.1	5
232	Real-world use of biological drugs in patients with psoriasis/psoriatic arthritis: a retrospective, population-based study of years 2010-2014 from Southern Italy. Giornale Italiano Di Dermatologia E Venereologia, 2020, 155, 441-451.	0.8	5
233	IN VITRO COMPETITIVE INHIBITION OF DESIPRAMINE HYDROXYLATION BY ALFENTANIL AND FENTANYL IN HUMAN LIVER MICROSOMES. Anesthesiology, 1985, 63, A305.	1.3	4
234	Characterization of Desmethylimipramine 2â€Hydroxylation in Human Foetal and Adult Liver Microsomes. Acta Pharmacologica Et Toxicologica, 1986, 58, 277-281.	0.0	4

EDOARDO SPINA

#	Article	IF	CITATIONS
235	Can zinc depletion play a role in LEV-induced hair loss? Considerations from a case study. Epilepsy and Behavior, 2013, 29, 254-255.	0.9	4
236	Reboxetine Adjuvant Therapy in Patients With Schizophrenia Showing a Suboptimal Response to Clozapine. Journal of Clinical Psychopharmacology, 2014, 34, 620-623.	0.7	4
237	<i>Serenoa repens</i> as an Endocrine Disruptor in a 10-Year-Old Young Girl: A New Case Report. Pharmacology, 2015, 96, 41-43.	0.9	4
238	Drug-induced Urinary Retention: An Analysis of a National Spontaneous Adverse Drug Reaction Reporting Database. European Urology Focus, 2022, 8, 1424-1432.	1.6	4
239	Epidemiology and pathoetiology of neurological syndromes with hyperthermia. Functional Neurology, 1995, 10, 111-9.	1.3	4
240	Optimization of Therapy in Patients with Epilepsy and Psychiatric Comorbidities: Key Points. Current Neuropharmacology, 2023, 21, 1755-1766.	1.4	4
241	Debrisoquine oxidation in schizophrenic patients treated with neuroleptics. Pharmacological Research Communications, 1988, 20, 1103-1104.	0.2	3
242	Effects of valpromide and viloxazine on the elimination of carbamazepine-10,11-epoxide, an active metabolite of carbamazepine. Pharmacological Research, 1989, 21, 111-112.	3.1	3
243	Pharkacoxinetic interactions between tricyclic antidepressants and other psychotropic drugs in depressed patients. Pharmacological Research, 1992, 25, 210-211.	3.1	3
244	Pharmacokinetic drug interactions with oral haloperidol in adults: dose correction factors from a combined weighted analysis. Expert Opinion on Drug Metabolism and Toxicology, 2022, 18, 135-149.	1.5	3
245	Prevalence of primary cutis verticis gyrata in a psychiatric population: association with chromosomal fragile sites. Acta Dermato-Venereologica, 1990, 70, 483-6.	0.6	3
246	Decreased Plasma Concentrations of Imipramine and Desipramine Following Cholestyramine Intake in Depressed Patients. Therapeutic Drug Monitoring, 1994, 16, 432-434.	1.0	2
247	Transient Global Amnesia as a Presenting Aura or Epilepsy?. Headache, 2014, 54, 1233-1235.	1.8	2
248	Efficacy of Antidepressants: Issues Related to Bias in Clinical Trials. Clinical Therapeutics, 2016, 38, e2.	1.1	2
249	Pharmacokinetics of Paliperidone Palmitate in Schizophrenic Patients: Data from a Routine Therapeutic Drug Monitoring Service. Clinical Therapeutics, 2017, 39, e50-e51.	1.1	2
250	Valproic acid-amitriptyline interaction in man. Therapeutic Drug Monitoring, 1986, 8, 382-3.	1.0	2
251	Desmethylimipramine overdose: nonlinear kinetics in a slow hydroxylator. Therapeutic Drug Monitoring, 1985, 7, 239-41.	1.0	2

Clinical validation of a combinatorial PharmAcogeNomic approach in major Depressive disorder: an Observational prospective RAndomized, participant and rater-blinded, controlled trial (PANDORA) Tj ETQq0 0 0 rgB0./Overloc 10 Tf 50

EDOARDO SPINA

#	Article	IF	CITATIONS
253	Pharmacogenomics of Depression. Advances in Biological Psychiatry, 2010, , 58-74.	0.2	1
254	Evaluation of acute Cardiovascular effects of immediate-release Methylphenidate in children and adolescents with attention deficit Hyperactivity disorder. Clinical Therapeutics, 2015, 37, e47.	1.1	1
255	Mood Stabilizers. , 2016, , 177-203.		1
256	Single-dose kinetics of an enteric-coated formulation of carbamazepine-10,11-epoxide, an active metabolite of carbamazepine. Therapeutic Drug Monitoring, 1988, 10, 382-5.	1.0	1
257	Prevalence of cardiac conduction disturbances during carbamazepine treatment: preliminary data. Functional Neurology, 1987, 2, 563-7.	1.3	1
258	Intra-daily oscillations in dipropylacetic acid plasma levels with two or three daily doses of dipropylacetamide in epileptic patients. Italian Journal of Neurological Sciences, 1983, 4, 173-177.	0.1	0
259	Genetic aspects of tricyclic antidepressants metabolism: Clinical implications. Pharmacological Research, 1990, 22, 467.	3.1	0
260	Post-marketing drug surveillance: Preliminary data of an experience in hospitalized patients. Pharmacological Research, 1990, 22, 471.	3.1	0
261	NEUROLEPTIC-INDUCED ACUTE DYSTONIC REACTIONS: PREVALENCE, RISK FACTORS AND RELATIONSHIP TO DEFECTIVE DRUG OXIDATION. Clinical Neuropharmacology, 1992, 15, 269B.	0.2	0
262	Cytochrome P450IID6-mediated oxidation and acute neuroleptic-induced adverse effects. Pharmacological Research, 1992, 26, 119.	3.1	0
263	Preventing drug interactions with antidepressants in the elderly. Aging Health, 2007, 3, 231-243.	0.3	0
264	Reply to Lian et al Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2010, 34, 1159.	2.5	0
265	6. Predicting effects of antiepileptics on mood: Clues from knowledge about mechanisms of action. Epilepsy and Behavior, 2010, 17, 580-581.	0.9	0
266	Aripiprazole in children with multiple-complex developmental disorder (McDD): a case series. European Psychiatry, 2011, 26, 1284-1284.	0.1	0
267	Treatment adherence is improved in patients affected by schizophrenia or bipolar disorder switching from quetiapine IR to quetiapine XR. International Clinical Psychopharmacology, 2012, 28, e50-e51.	0.9	0
268	There is a high level of variability in antipsychotic treatment for patients affected by schizophrenia or bipolar disorder. International Clinical Psychopharmacology, 2012, 28, e51-e52.	0.9	0
269	PMH25 Cost and Use of Resources in Patients with Schizophrenia and Bipolar Disorder Switching from Immediate Release Quetiapine (QTP-IR) to Extended Release Quetiapine (QTP-XR) in Italy- the IBIS Study. Value in Health, 2012, 15, A86.	0.1	0
270	PPO2O—Effects of aripiprazole and risperidone on ventricular repolarization in children and adolescents. Clinical Therapeutics, 2013, 35, e23-e24.	1.1	0

#	Article	IF	CITATIONS
271	Prescribing patterns of antiepileptic drugs and interaction risk in general practice. Journal of the Neurological Sciences, 2013, 333, e23.	0.3	0
272	PP178—Antiepileptic Drugs: Prescribing Patterns and Interaction Risk in General Practice. Clinical Therapeutics, 2013, 35, e73-e74.	1.1	0
273	P.1.a.016 CHL1 gene: a new promising antidepressant response marker in major depression. European Neuropsychopharmacology, 2013, 23, S168-S169.	0.3	0
274	P.1.c.012 Open-label study comparing the efficacy and tolerability of aripiprazole and risperidone in the treatment of children with autism spectrum disorder and ADHD. European Neuropsychopharmacology, 2015, 25, S200-S201.	0.3	0
275	Generic olanzapine substitution in patients with Schizophrenia: assessment of serum concentrations and therapeutic response after switching. Clinical Therapeutics, 2015, 37, e48.	1.1	0
276	EKG parameters in children and adolescents treated with second-generation antipsychotics: a 1-year prospective follow-up study. European Neuropsychopharmacology, 2016, 26, S745-S746.	0.3	0
277	EKG Parameters in Children and Adolescents Treated with Second-Generation Antipsychotics: A 24-Months Prospective Follow-Up Study. Clinical Therapeutics, 2017, 39, e43.	1.1	0
278	P481 Effectiveness and safety profile of biological therapy in inflammatory bowel disease: real life data from an active pharmacovigilance project. Journal of Crohn's and Colitis, 2021, 15, S470-S471.	0.6	0
279	Therapeutic continuity in the treatment of psychiatric disorders. Global & Regional Health Technology Assessment, 2015, 2, GRHTA.5000197.	0.2	0
280	Biosimilars in Pediatric Inflammatory Bowel Diseases: A Systematic Review and Real Life-Based Evidence. Frontiers in Pharmacology, 2022, 13, 846151.	1.6	0